Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06545929Phase 2Completed

Study of Sunobinop on Craving in Alcohol Use Disorder

Role: lead

NCT06545916Phase 2Completed

Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Role: lead

NCT07543276Phase 1Completed

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

Role: lead

All 3 trials loaded